A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.